{"id":"NCT00740246","sponsor":"American Regent, Inc.","briefTitle":"Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia","officialTitle":"A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2006-02","completion":"2006-05","firstPosted":"2008-08-22","resultsPosted":"2025-04-18","lastUpdate":"2025-04-18"},"enrollment":594,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"VIT-45","otherNames":["ferric carboxymaltose"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"VIT-45 on Day 0, then Placebo on Day 7","type":"EXPERIMENTAL"},{"label":"Placebo on Day 0, then VIT-45 on Day 7","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia","primaryOutcome":{"measure":"Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period","timeFrame":"Day 0 to 7","effectByArm":[{"arm":"ViT-45","deltaMin":174,"sd":null},{"arm":"Placebo","deltaMin":114,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":584},"commonTop":["Headache"]}}